PACKAGE LEAFLET: INFORMATION FOR THE USER
Immufalk 100 mg film-coated tablets
Azathioprine
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
Immufalk contains the active substance azathioprine, which belongs to a group of medicines called immunosuppressants, which reduce the activity of your immune system.
Immufalk can be used to help your body accept a transplanted organ, such as a new kidney, heart, or liver, or to treat certain diseases in which your immune system is reacting against your own body (autoimmune diseases).
Immufalk may also be used alone or in combination with other medicines to treat:
Your doctor has chosen this medicine to suit you and your condition.
Immufalk can be used alone, but it is most often used in combination with other medicines.
It may take weeks or months before a therapeutic effect is observed.
Do not take Immufalk
Warnings and precautions
Consult your doctor before starting to take Immufalk.
You should not take Immufalk unless you can be monitored for adverse effects. You should immediately inform your doctor if you develop throat ulcers, fever, infections, bruising, or bleeding.
Consult your doctor immediately:
Consult your doctor before starting to take Immufalk:
Liver damage
Treatment with Immufalk may affect your liver, and your doctor will periodically monitor your liver function. Inform your doctor if you experience symptoms of liver damage (see section 4 "Possible side effects")
Infections
When you receive treatment with Immufalk, the risk of viral, fungal, and bacterial infections is greater, and these infections can be more severe. See also section 4.
Before starting treatment, inform your doctor if you have had or not had varicella, herpes, or hepatitis B (a liver disease caused by a virus). When you take Immufalk, avoid contact with people who have varicella or herpes zoster.
Pellagra
Inform your doctor immediately if you notice diarrhea, a pigmented rash (dermatitis), deterioration of memory, reasoning, and thinking ability (dementia), as these symptoms may indicate a deficiency of vitamin B3 (niacin/pellagra deficiency).
NUDT15 gene mutation
If you have an inherited mutation in the NUDT15 gene (a gene involved in the breakdown of azathioprine in the body), you have a higher risk of infections and hair loss, and in this case, your doctor may give you a lower dose.
Your doctor may also perform genetic tests (e.g., analyze your TPMT and/or NUDT15 genes) before or during your treatment to determine if your response to this medicine may be affected by your genetics. Your doctor may change your dose of azathioprine after these tests.
If you are receiving immunosuppressive treatment, taking Immufalk may increase your risk of:
Taking Immufalk may increase your risk of:
If you are not sure if any of the above applies to you, talk to your doctor, nurse, or pharmacist before taking Immufalk.
Blood tests
You will need to have a blood test once a week for the first 8 weeks of treatment. You may need more frequent blood tests if:
It is important to use effective contraception (such as condoms) since Immufalk can cause birth defects in both men and women.
Other medicines and Immufalk
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This is because Immufalk can affect how some medicines work. Also, other medicines can affect how Immufalk works. In particular, tell your doctor if you are taking or plan to take:
If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before taking Immufalk.
Receiving vaccines while taking Immufalk
If you need to receive a vaccine, talk to your doctor or nurse before doing so. If you take Immufalk, you should not receive a live attenuated vaccine (e.g., flu vaccine, measles vaccine, BCG vaccine, etc.) until at least 3 months after the end of treatment or until your doctor tells you it is safe to do so. This is because some vaccines can cause infection if you receive them while taking Immufalk. If you need inactivated vaccines, your doctor may need to monitor your immune response.
Immufalk with food and drinks
You should take your medicine at least 1 hour before or 2 hours after taking milk or dairy products.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Do not take Immufalk if you are pregnant unless your doctor tells you to. Inform your doctor if you are pregnant or think you may be pregnant. Both male and female patients of childbearing age must use contraceptive measures that are not intrauterine devices (e.g., spiral or copper T).
You should continue to use contraception for 6 months after treatment with Immufalk. If you have fertility problems due to chronic uremia, you should know that fertility usually returns to normal after transplantation, and you should use contraceptives.
.
Do not breast-feed during treatment with Immufalk, as the metabolic products produced in the body pass into breast milk and can harm the baby.
Driving and using machines
It is safe to drive or use machines while taking Immufalk unless you experience dizziness. Dizziness may be increased by alcohol, so you should not drive or use machines if you have taken alcohol.
Immufalk contains lactose
This medicine contains lactose. If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Follow your doctor's or pharmacist's administration instructions for this medication exactly. If in doubt, consult your doctor or pharmacist again.
The amount of Immufalk may vary from one patient to another and will be prescribed by your doctor. The dose depends on the disorder being treated.
You can take Immufalk with food or on an empty stomach, but the choice of method should be the same every day. Some patients feel nauseous when they are first given Immufalk, which can be relieved by taking the tablets after meals.
When taking Immufalk, your doctor will regularly perform blood tests. This is to check the number and type of cells present in your blood and to ensure that your liver is functioning properly.
Your doctor may also request other blood and urine tests to monitor the functioning of your kidneys and measure uric acid levels. Uric acid is a natural substance produced in your body, and uric acid levels may increase while taking Immufalk. High uric acid levels can damage your kidneys.
Occasionally, your doctor may change your dose of Immufalk as a result of these tests.
Swallow the tablets whole with plenty of liquid (at least 200 ml). Do not chew them. The tablets should not be broken or crushed.
It is essential that caregivers are aware of the need to handle this medication safely. If you or your caregiver handle broken tablets, wash your hands immediately. Consult your doctor or pharmacist for advice.
Dose
Adults who have received an organ transplant: on the first day of treatment, the usual dose is up to 5 mg per kilogram of body weight, and subsequently, the usual daily dose is between 1 mg and 4 mg per kilogram of body weight. During treatment, your doctor will adjust the dose based on your reaction to the medication.
Adults with other disorders: the usual initial dose is between 1 mg and 3 mg per kilogram of body weight, and subsequently, the usual daily dose is less than between 1 mg and 3 mg per kilogram of body weight. During treatment, your doctor will adjust the dose based on your reaction to the medication.
Use in children and adolescents
Immufalk is not recommended for use in children under 18 years of age due to insufficient data on the treatment of chronic juvenile arthritis, systemic lupus erythematosus, dermatomyositis, and polyarteritis nodosa.
For other indications, the same dosage recommendation is used in children and adolescents as in adults.
Children who are considered overweight may require a higher dose.
Elderly patients:
Elderly patients may need to reduce the dose.
Patients with liver or kidney disorders may need to reduce the dose.
Patients with severe liver problems should not take Immufalk.
Your doctor will decide the duration of treatment with Immufalk.
If you think the effect of Immufalk is too strong or too weak, please consult your doctor.
If you take more Immufalk than you should
Contact your doctor, pharmacist, or the nearest hospital immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 915 620 420, indicating the medication and the amount ingested.
If you forget to take Immufalk
Do not take a double dose to make up for the missed dose. Inform your doctor if you forget to take a dose. If it is almost time for the next dose, skip the missed dose and take the next dose at the scheduled time. Otherwise, take it as soon as you remember and then take the doses as you would normally.
If you interrupt treatment with Immufalk
Any suspension of Immufalk should be done gradually and under careful monitoring. Please consult your doctor.
If you have any other questions about the use of this product, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
Severe side effects:
If you experience any of the following severe side effects, consult your doctor or go to the hospital immediately:
Contact your doctor immediately if you develop any of the following side effects:
The following side effects have also been reported:
Very rare: may affect up to 1 in 10,000 users
Frequency not known: cannot be estimated from available data
Reporting side effects
If you experience side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. You can also report them directly through the Spanish Medicines Surveillance System for Human Use: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Store in the original package to protect it from light.
Do not use Immufalk after the expiration date shown on the package and blister pack after "EXP". The expiration date is the last day of the month indicated.
Do not use Immufalk if you notice any visible signs of deterioration.
Medicines should not be disposed of through wastewater or household waste. Deposit the packages and medicines you no longer need in the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of packages and medicines you no longer need. This will help protect the environment.
Composition of Immufalk
The active ingredientis azathioprine.
Each film-coated tablet contains 100 mg of azathioprine.
The other ingredients(excipients) are:
Core of the tablet: sodium croscarmellose, anhydrous colloidal silica, lactose monohydrate, microcrystalline cellulose, sodium stearyl fumarate, pregelatinized corn starch, povidone K25.
Coating of the tablet: macrogol 3350, polysorbate 80, polyvinyl alcohol, talc
Appearance of the product and package contents
Immufalk 100 mg film-coated tablets are yellow, round, biconvex tablets, 10.0 mm in size, marked with "100" on one side.
The tablets should not be crushed. If the tablet coating is damaged or the tablet is completely crushed, avoid skin contamination or inhalation of tablet particles. For long-term dosing, other medications containing 25 mg should be used if necessary.
Packages:
The film-coated tablets are packaged in PVC/aluminum blisters in a cardboard box.
Immufalk 100 mg film-coated tablets are available in packages of: 20, 30, 50, 60, 90, or 100 film-coated tablets.
Not all package sizes may be marketed.
Marketing authorization holder and manufacturer
Dr. Falk Pharma GmbH
Leinenweberstr. 5
79108 Freiburg
Germany
Phone +49 (0) 761 / 1514-0
Fax +49(0) 761 / 1514-321
Email: [email protected]
You can request more information about this medication from the local representative of the marketing authorization holder:
Dr. Falk Pharma España
Camino de la zarzuela, 21
28023 Madrid
Spain
Phone +34 91 3729508
This medication is authorized in the Member States of the European Economic Area under the following names:
Germany and Portugal: Azafalk.
Spain: Immufalk.
Date of the last revision of this leaflet: July 2025
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS)http://www.aemps.es/
---------------------------------------------------------------------------------------------------------------------------
The following information is intended only for healthcare professionals:
Immufalk 75 mg film-coated tablets
Handling and disposal instructions
There are no risks associated with handling tablets with intact coating. In this case, no special safety precautions are necessary.
However, if the film-coated tablets have been crushed, Immufalk film-coated tablets should be handled strictly according to the guidelines for handling cytotoxic agents. Excess medication and contaminated devices should be stored temporarily in clearly labeled containers. Any unused product or waste material should be disposed of according to local requirements.
The average price of IMMUFALK 100 MG FILM-COATED TABLETS in October, 2025 is around 20.79 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for IMMUFALK 100 MG FILM-COATED TABLETS – subject to medical assessment and local rules.